Labcorp Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.5%projected annual EPS growth
Analyst Coverage
16analysts covering
FY Revenue (est.)
$14.7Bnext fiscal year
FY EPS (est.)
$18.35next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 22 Oct 2026 |
| Q4 2026 Earnings Release | 11 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Enterprise Revenue Growth (YoY) Quarterly5.8%Target: 5.0% to 6.1%
Adjusted Diluted EPS Quarterly4.3Target: $17.70 to $18.35
Biopharma Laboratory Services (BLS) Backlog Quarterly8.6BTarget: Continued year-over-year expansion
Free Cash Flow AnnuallyTarget: $1.24B to $1.36B
Watch Items
- PAMA (Protecting Access to Medicare Act) and regulatory reimbursement updatesTrigger: Any adverse legislative shifts or implementation of scheduled price cutsAction: Re-evaluate long-term diagnostic segment margin projections and adjust pricing models.
- Integration of acquisitions (including Invitae assets and regional lab partnerships)Trigger: Delays in closing or higher-than-expected integration costs impacting operating leverageAction: Assess capital allocation efficiency and adjust near-term operating margin guidance.
- Early Development transitional actions within Biopharma Laboratory ServicesTrigger: Flat organic growth persisting into the second half of 2026Action: Review cost-reduction initiatives and capacity utilization across preclinical testing sites.
Research as of 2 Sep 2026